Endocyte raises $26 million to fund clinical anticancer pipeline
This article was originally published in Scrip
Executive Summary
Endocyte has raised $26 million in an extension of its series C financing. The US biotechnology company has a broad pipeline of drug candidates for the treatment of various cancers and inflammatory diseases, including six anticancer drugs in clinical trials.